Differential effects of extracellular vesicles secreted by mesenchymal stem cells from different sources on glioblastoma cells

Expert Opinion on Biological Therapy

Volumn 15, Issue 4, 2015, Pages 495-504

  Del Fattore, Andrea ^a   Luciano, Rosa ^a   Saracino, Rossana ^a   Battafarano, Giulia ^a   Rizzo, Cristiano ^a   Pascucci, Luisa ^b   Alessandri, Giulio ^c   Pessina, Augusto ^d   Perrotta, Antonio ^e   Fierabracci, Alessandra ^a   Muraca, Maurizio ^a,f  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e Division of Plastic Surgery   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

Author keywords

Extracellular vesicles; Glioblastoma; Mesenchymal stem stromal cells; Vincristine

Indexed keywords

NANOCARRIER; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADIPOSE TISSUE; APOPTOSIS; ARTICLE; BONE MARROW; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; EXTRACELLULAR VESICLE; FLUORESCENCE ACTIVATED CELL SORTING; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; MESENCHYMAL STEM CELL; SECRETORY VESICLE; UMBILICAL CORD; ADULT; BONE MARROW CELL; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; EXOSOME; MESENCHYMAL STROMA CELL; PATHOLOGY; PHYSIOLOGY; SECRETION (PROCESS); TUMOR CELL LINE; YOUNG ADULT;

ADIPOSE TISSUE; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BONE MARROW CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; EXOSOMES; GLIOBLASTOMA; HUMANS; MESENCHYMAL STROMAL CELLS; UMBILICAL CORD; VINCRISTINE; YOUNG ADULT;

EID: 84925270282     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.997706     Document Type: Article

References (60)

1. Ankrum J, Karp JM. Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol Med 2010;16(5):203-9
2. Ley K, Laudanna C, Cybulsky MI, et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007;7(9):678-89
3. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009;4(3):206-16
4. Teo GSL, Ankrum JA, Martinelli R, et al. Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-a-activated endothelial cells via both leukocyte-like and novel mechanisms. Stem Cells 2012;30(11):2472-86
5. Ip JE, Wu Y, Huang J, et al. Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol Biol Cell 2007;18(8):2873-82
6. Rüster B, Göttig S, Ludwig RJ, et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006;108(12):3938-44
7. Liu ZJ, Zhuge Y, Velazquez OC. Trafficking and differentiation of mesenchymal stem cells. J Cell Biochem 2009;106(6):984-91
8. Honczarenko M, Le Y, Swierkowski M, et al. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006;24(4):1030-41
9. Ponte AL, Marais E, Gallay N, et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007;25(7):1737-45
10. Baek SJ, Kang SK, Ra JC. In vitro migration capacity of human adipose tissue-derived mesenchymal stem cells reflects their expression of receptors for chemokines and growth factors. Exp Mol Med 2011;43(10):596-603
11. Son BR, Marquez-Curtis LA, Kucia M, et al. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 2006;24(5):1254-64
12. Bain O, Detela G, Kim HW, et al. Altered hMSC functional characteristics in short-term culture and when placed in low oxygen environments: implications for cell retention at physiologic sites. Regen Med 2014;9(2):153-65
13. Chamberlain G, Smith H, Rainger GE, et al. Mesenchymal stem cells exhibit firm adhesion, crawling, spreading and transmigration across aortic endothelial cells: effects of chemokines and shear. PLoS One 2011;6(9):e25663
14. Teo GS, Yang Z, Carman CV, et al. Intravital imaging of mesenchymal stem cell trafficking and association with platelets and neutrophils. Stem Cells 2014. [Epub ahead of print]
15. De Becker A, Van Hummelen P, Bakkus M, et al. Migration of cultureexpanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3. Haematologica 2007;92(4):440-9
16. Mohyeldin A, Garzon-Muvdi T, Quinones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 2010;7(2):150-61
17. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7
18. Kidd S, Spaeth E, Dembinski JL, et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009;27:2614-23
19. Spaeth EL, Dembinski JL, Sasser AK, et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009;4:e4992
20. Droujinine IA, Eckert MA, Zhao W. To grab the stroma by the horns: from biology to cancer therapy with mesenchymal stem cells. Oncotarget 2013;4:651-64
21. Ljujic B, Milovanovic M, Volarevic V, et al. Human mesenchymal stem cells creating an immunosuppressive environment and promote breast cancer in mice. Sci Rep 2013;3:2298
22. Otsu K, Das S, Houser SD, et al. Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood 2009;113:4197-205
23. Shah K. Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev 2012;64:739-48
24. Klopp AH, Gupta A, Spaeth E, et al. Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells 2011;29:11-19
25. Porada CD, Almeida-Porada G. Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery. Adv Drug Deliv Rev 2010;62:1156-66
26. Pessina A, Bonomi A, Cocce V, et al. Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS One 2011;6:e28321
27. Fan L, Lin C, Zhuo S, et al. Transplantation with survivin-engineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction. Eur J Heart Fail 2009;11:1023-30
28. Meyerrose TE, Roberts M, Ohlemiller KK, et al. Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease. Stem Cells 2008;26:1713-22
29. Wang F, Dennis JE, Awadallah A, et al. Transcriptional profiling of human mesenchymal stem cells transduced with reporter genes for imaging. Physiol Genomics 2009;37:23-34
30. Xiang J, Tang J, Song C, et al. Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma. Cytotherapy 2009;11:516-26
31. Zhang XY, La Russa VF, Reiser J. Transduction of bone-marrow-derived mesenchymal stem cells by using lentivirus vectors pseudotyped with modified RD114 envelope glycoproteins. J Virol 2004;78:1219-29
32. Bosch P, Fouletier-Dilling C, Olmsted-Davis EA, et al. Efficient adenoviral-mediated gene delivery into porcine mesenchymal stem cells. Mol Reprod Dev 2006;73:1393-403
33. Bosch P, Stice SL. Adenoviral transduction of mesenchymal stem cells. Methods Mol Biol 2007;407:265-74
34. Roelants V, Labar D, de Meester C, et al. Comparison between adenoviral and retroviral vectors for the transduction of the thymidine kinase PET reporter gene in rat mesenchymal stem cells. J Nucl Med 2008;49:1836-44
35. Kumar S, Mahendra G, Nagy TR, Ponnazhagan S. Osteogenic differentiation of recombinant adenoassociated virus 2-transduced murine mesenchymal stem cells and development of an immunocompetent mouse model for ex vivo osteoporosis gene therapy. Hum Gene Ther 2004;15:1197-206
36. Gao P, Ding Q, Wu Z, et al. Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett 2010;290:157-66
37. Ling X, Marini F, Konopleva M, et al. Mesenchymal stem cells overexpressing IFN-beta inhibit breast cancer growth and metastases through Stat3 signaling in a syngeneic tumor model. Cancer Microenviron 2010;3:83-95
38. Mueller LP, Luetzkendorf J, Widder M, et al. TRAIL-transduced multipotent mesenchymal stromal cells (TRAILMSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo. Cancer Gene Ther 2011;18:229-39
39. Grisendi G, Bussolari R, Cafarelli L, et al. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res 2010;70:3718-29
40. Biancone L, Bruno S, Deregibus MC, et al. Therapeutic potential of mesenchymal stem cell-derived microvesicles. Nephrol Dial Transplant 2012;27:3037-42
41. Doorn J, Moll G, Le Blanc K, et al. Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements. Tissue Eng Part B Rev 2012;18:101-15
42. Fierabracci A, Del Fattore A, Luciano R, et al. Recent advances in mesenchymal stem cell immunomodulation. The role of microvesicles. Cell Transplant 2013. [Epub ahead of print]
43. Katsuda T, Kosaka N, Takeshita F, Ochiya T. The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. Proteomics 2013;13:1637-53
44. Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol 2009;19:43-51
45. Maiorana A, Fierabracci A, Cianfarani S. Isolation and characterization of omental adipose progenitor cells in children: a potential tool to unravel the pathogenesis of metabolic syndrome. Horm Res 2009;72:348-58
46. Lamparski HG, Metha-Damani A, Yao J-Y, et al. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 2002;270:211-26
47. Budoni M, Fierabracci A, Luciano R, et al. The immunosuppressive effect of mesenchymal stromal cells on B lymphocytes is mediated by membrane vesicles. Cell Transplant 2013;22:369-79
48. Herrera MB, Bussolati B, Bruno S, et al. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int 2007;72:430-41
49. Ji JF, He BP, Dheen ST, Tay SS. Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. Stem Cells 2004;22:415-27
50. Togel F, Hu Z, Weiss K, et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiationindependent mechanisms. Am J Physiol Renal Physiol 2005;289:F31-42
51. Kucerova L, Matuskova M, Hlubinova K, et al. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer 2010;9:129
52. Zhu W, Huang L, Li Y, et al. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett 2012;315:28-37
53. Bruno S, Collino F, Deregibus MC, et al. Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth. Stem Cells Dev 2013;22:758-71
54. Yu JM, Jun ES, Bae YC, Jung JS. Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells Dev 2008;17:463-73
55. Dasari VR, Kaur K, Velpula KK, et al. Downregulation of Focal Adhesion Kinase (FAK) by cord blood stem cells inhibits angiogenesis in glioblastoma. Aging (Albany NY) 2010;2:791-803
56. Hu B, Guo P, Bar-Joseph I, et al. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrinepathway. Oncogene 2007;26:5577-86
57. Giannopoulou E, Dimitropoulos K, Argyriou AA, et al. An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines. Invest New Drugs 2010;28:554-60
58. Tan X, Wang S, Zhu L, et al. cAMP response element-binding protein promotes gliomagenesis by modulating the expression of oncogenic microRNA-23a. Proc Natl Acad Sci USA 2012;109:15805-10
59. Pascucci L, Cocce V, Bonomi A, et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: A new approach for drug delivery. J Control Release 2014;192C:262-70
60. Tian X, Zhu M, Nie G. How can nanotechnology help membrane vesiclebased cancer immunotherapy development? Hum Vaccin Immunother 2013;9:222-5